Ivonescimab and chemotherapy before surgery for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called ivonescimab combined with chemotherapy, given before surgery for esophageal cancer. The goal is to see if this combination can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of esophageal cancer called squamous cell carcinoma that has not spread far (stage II or III).
- You must be healthy enough for surgery and have a performance status of 0 or 1 (able to carry out daily activities).
- Your blood counts, liver, kidney, and lung function must be within certain ranges (e.g., white blood cells > 4.0, platelets > 100).
- You cannot have had any previous cancer treatment like radiation, chemo, or immunotherapy.
- You must not have an active autoimmune disease, uncontrolled heart condition, or active infection.
- You must be willing to provide tissue and blood samples and follow study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called Ivonescimab (AK112) combined with two chemotherapy drugs (Abraxane and cisplatin) given before surgery for esophageal cancer. The goal is to see if this combination can shrink tumors and improve surgery outcomes for patients with locally advanced disease.
This trial tests a new immunotherapy drug (ivonescimab, also called AK112) combined with chemotherapy before surgery for people with esophageal squamous cell cancer that can be completely removed. The goal is to see if adding immunotherapy before surgery helps shrink the tumor and improve outcomes.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
This trial tests a drug called Adebrelimab combined with chemotherapy before surgery for esophageal cancer. It aims to shrink the tumor and make it easier to remove completely.
This trial tests a combination of low-dose radiation, chemotherapy, and immunotherapy before surgery for esophageal cancer. The goal is to see if this approach helps shrink the tumor and improve outcomes.
Hear when a new Esophageal Squamour Cell Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.